Analyst Expectations for Denali Therapeutics's Future
Portfolio Pulse from Benzinga Insights
In the last 3 months, 5 analysts have offered 12-month price targets for Denali Therapeutics (NASDAQ:DNLI), with an average price target of $75.6, a 34.21% increase over the past month. The company has received 2 bullish, 3 somewhat bullish, and no bearish ratings.
June 21, 2023 | 4:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Denali Therapeutics has an average 12-month price target of $75.6, up 34.21% in the past month, with 2 bullish and 3 somewhat bullish ratings from 5 analysts.
The increase in the average price target and the overall positive analyst ratings suggest a bullish outlook for Denali Therapeutics in the short term. The 34.21% increase in the price target over the past month indicates growing confidence in the company's prospects, which could positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100